Literature DB >> 15760591

New hope for systemic sclerosis patients with digital ulcers.

John Varga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15760591     DOI： 10.1007/s11926-005-0064-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  2 in total

1.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

2.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Authors:  F M Wigley; J R Seibold; R A Wise; D A McCloskey; W P Dole
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666
  2 in total
  1 in total

Review 1.  The diagnosis and treatment of Raynaud's phenomenon: a practical approach.

Authors:  Janet E Pope
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.